Bank of New York Mellon’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-17,893
| Closed | -$39.5K | – | 4433 |
|
|
2023
Q2 | $39.5K | Hold |
17,893
| – | – | ﹤0.01% | 4209 |
|
|
2023
Q1 | $45.4K | Hold |
17,893
| – | – | ﹤0.01% | 4208 |
|
|
2022
Q4 | $33.5K | Hold |
17,893
| – | – | ﹤0.01% | 4290 |
|
|
2022
Q3 | $46K | Sell |
17,893
-2,185
| -11% | -$5.44K | ﹤0.01% | 4341 |
|
|
2022
Q2 | $39K | Sell |
20,078
-117,016
| -85% | -$255K | ﹤0.01% | 4396 |
|
|
2022
Q1 | $407K | Sell |
137,094
-157
| -0.1% | -$591 | ﹤0.01% | 3837 |
|
|
2021
Q4 | $616K | Sell |
137,251
-2,908
| -2% | -$13.8K | ﹤0.01% | 3660 |
|
|
2021
Q3 | $682K | Buy |
140,159
+12,712
| +10% | +$70.1K | ﹤0.01% | 3626 |
|
|
2021
Q2 | $869K | Sell |
127,447
-2,836
| -2% | -$22.9K | ﹤0.01% | 3503 |
|
|
2021
Q1 | $920K | Sell |
130,283
-1,568
| -1% | -$11.3K | ﹤0.01% | 3377 |
|
|
2020
Q4 | $825K | Sell |
131,851
-1,371
| -1% | -$8.07K | ﹤0.01% | 3357 |
|
|
2020
Q3 | $721K | Sell |
133,222
-10,145
| -7% | -$50.2K | ﹤0.01% | 3305 |
|
|
2020
Q2 | $748K | Buy |
143,367
+22,983
| +19% | +$102K | ﹤0.01% | 3265 |
|
|
2020
Q1 | $379K | Sell |
120,384
-221
| -0.2% | -$815 | ﹤0.01% | 3503 |
|
|
2019
Q4 | $486K | Buy |
120,605
+8,080
| +7% | +$28K | ﹤0.01% | 3606 |
|
|
2019
Q3 | $486K | Buy |
112,525
+4,706
| +4% | +$18.8K | ﹤0.01% | 3550 |
|
|
2019
Q2 | $430K | Sell |
107,819
-34,676
| -24% | -$165K | ﹤0.01% | 3673 |
|
|
2019
Q1 | $764K | Buy |
142,495
+4,213
| +3% | +$27.2K | ﹤0.01% | 3335 |
|
|
2018
Q4 | $710K | Buy |
138,282
+1,906
| +1% | +$14.5K | ﹤0.01% | 3293 |
|
|
2018
Q3 | $1.32M | Buy |
136,376
+7,332
| +6% | +$74K | ﹤0.01% | 3096 |
|
|
2018
Q2 | $1.32M | Buy |
129,044
+11,980
| +10% | +$136K | ﹤0.01% | 3101 |
|
|
2018
Q1 | $1.52M | Sell |
117,064
-53,785
| -31% | -$801K | ﹤0.01% | 2968 |
|
|
2017
Q4 | $3.06M | Sell |
170,849
-2,253
| -1% | -$47K | ﹤0.01% | 2596 |
|
|
2017
Q3 | $4.34M | Buy |
173,102
+603
| +0.3% | +$14K | ﹤0.01% | 2404 |
|
|
2017
Q2 | $4.16M | Buy |
172,499
+88,454
| +105% | +$1.96M | ﹤0.01% | 2418 |
|
|
2017
Q1 | $1.62M | Buy |
84,045
+12,505
| +17% | +$197K | ﹤0.01% | 2981 |
|
|
2016
Q4 | $1.1M | Buy |
71,540
+5,640
| +9% | +$73.2K | ﹤0.01% | 3209 |
|
|
2016
Q3 | $857K | Buy |
65,900
+20,760
| +46% | +$275K | ﹤0.01% | 3257 |
|
|
2016
Q2 | $628K | Buy |
45,140
+4,616
| +11% | +$68K | ﹤0.01% | 3419 |
|
|
2016
Q1 | $615K | Sell |
40,524
-236
| -0.6% | -$3.61K | ﹤0.01% | 3331 |
|
|
2015
Q4 | $773K | Sell |
40,760
-188,982
| -82% | -$3.61M | ﹤0.01% | 3321 |
|
|
2015
Q3 | $4.37M | Sell |
229,742
-5,428
| -2% | -$135K | ﹤0.01% | 2315 |
|
|
2015
Q2 | $6.06M | Buy |
235,170
+91,949
| +64% | +$2.61M | ﹤0.01% | 2241 |
|
|
2015
Q1 | $4.48M | Buy |
143,221
+52,895
| +59% | +$1.52M | ﹤0.01% | 2369 |
|
|
2014
Q4 | $3.48M | Buy |
90,326
+89,336
| +9,024% | +$2.13M | ﹤0.01% | 2510 |
|
|
2014
Q3 | $24K | Hold |
990
| – | – | ﹤0.01% | 4195 |
|
|
2014
Q2 | $24K | Buy |
990
+6
| +0.6% | +$196 | ﹤0.01% | 4123 |
|
|
2014
Q1 | $36K | Hold |
984
| – | – | ﹤0.01% | 4113 |
|
|
2013
Q4 | $40K | Sell |
984
-107
| -10% | -$4.54K | ﹤0.01% | 4127 |
|
|
2013
Q3 | $42K | Buy |
1,091
+3
| +0.3% | +$107 | ﹤0.01% | 4059 |
|
|
2013
Q2 | $40K | Buy |
+1,088
| New | +$46.6K | ﹤0.01% | 4061 |
|
Bank of New York Mellon's PRTK Position: Q3 2023 in Review
Bank of New York Mellon sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 17,893 shares — an estimated $39.5K sold.
Bank of New York Mellon first reported a position in PRTK in Q2 2013 and held it in 41 quarters. The position peaked at $6.06M in Q2 2015. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Bank of New York Mellon reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Bank of New York Mellon sold 17,893 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $39.5K.
- Bank of New York Mellon first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 41 quarters.
- Bank of New York Mellon's Paratek Pharmaceuticals, Inc. position peaked at $6.06M in Q2 2015.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Bank of New York Mellon's 13F filing for Q3 2023, filed 24 Oct 2023.